Another pill but this one by Pfizer
[url=https://www.ft.com/content/848cce54-0d47-4488-b829-5539abddcf6e]Subscribe to read | Financial Times[/]
Pfizer’s Covid-19 oral antiviral drug cut the risk of hospitalisation or death by 89 per cent in a late-stage trial, creating a potential new tool in treating patients and combating the pandemic.
The US pharmaceutical company said on Friday it was stopping the trial due to the “overwhelming efficacy”. It will add the data for the drug known as Paxlovid to its rolling submission to the US Food and Drug Administration for an emergency use authorisation as soon as possible.
The trial focused on high-risk patients who were not yet hospitalised, with the interim analysis based on 1,219 patients enrolled by late September in sites across the world.
The data showed only 0.8 per cent of trial participants who took the antiviral drug within three days of getting symptoms were hospitalised, compared with 7 per cent who received a placebo. The results were similar to those treated within five days. None of the patients taking the drug died, compared with 1.6 per cent who received a placebo.
The results of the study suggest the drug is even more effective than the antiviral developed by Merck, which cut the risk of hospitalisation or death in half, although the trial results may not be directly comparable. Merck’s drug received its first authorisation, in the UK, on Thursday.
Sent from my iPad using Tapatalk


Reply With Quote



